UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000006450 |
|---|---|
| Receipt number | R000007497 |
| Scientific Title | Comparison Examination of efficacy and safety of new 5-ASA with Salazosulfapyridine preparation for ulcerative colitis. |
| Date of disclosure of the study information | 2011/10/01 |
| Last modified on | 2013/10/02 00:35:55 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Comparison Examination of efficacy and safety of new 5-ASA with Salazosulfapyridine preparation for ulcerative colitis.
Acronym
The change of an effect and side effects to ulcerative colitis when it changes from Salazosulfapyridine to Asacol is evaluated.
Scientific Title
Comparison Examination of efficacy and safety of new 5-ASA with Salazosulfapyridine preparation for ulcerative colitis.
Scientific Title:Acronym
The change of an effect and side effects to ulcerative colitis when it changes from Salazosulfapyridine to Asacol is evaluated.
Region
| Japan |
Condition
Condition
Ulcerative colitis
Classification by specialty
| Medicine in general | Gastroenterology |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
The proper dosage of Salazosulfapyridine to ulcerative colitis and Asacol is measured.
Basic objectives2
Safety
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
non-relapse rate by CAI score after two months
Key secondary outcomes
Base
Study type
Interventional
Study design
Basic design
Single arm
Randomization
Non-randomized
Randomization unit
Blinding
Open -no one is blinded
Control
Active
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
1
Purpose of intervention
Treatment
Type of intervention
| Medicine |
Interventions/Control_1
The efficacy and the safety of the Asacol is examined by administering Asacol 2.4g/day switching from less than Pentasa 4g/day, and the medication of Asacol is continued for 8 weeks if at all possible.
The efficacy and the safety of the Asacol is examined by administering Asacol 3.6g/day switching from more than Pentasa 4g/day, and the medication of Asacol is continued for 8 weeks if at all possible.
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 20 | years-old | <= |
Age-upper limit
| Not applicable |
Gender
Male and Female
Key inclusion criteria
Mild and moderate ulcerative colitis patients taking Salazosulfapyridine.
Key exclusion criteria
(1)Patients without agreement of this study
(2)Pregnant women and women suspected of being pregnant
(3)Patients with history of total or partial colectomy operation.
Target sample size
30
Research contact person
Name of lead principal investigator
| 1st name | |
| Middle name | |
| Last name | Tomoyoshi Shibuya |
Organization
Department of Internal Medicine,Juntendo University
Division name
Department of Gastroenterology
Zip code
Address
2-1-1 Hongo,Bunkyo ward,Tokyo,Japan
TEL
03-3813-3111
tomoyosi@juntendo.ac.jp
Public contact
Name of contact person
| 1st name | |
| Middle name | |
| Last name | Tomoyoshi Shibuya |
Organization
Department of Internal Medicine,Juntendo University
Division name
Department of Gastroenterology
Zip code
Address
2-1-1 Hongo,Bunkyo ward,Tokyo,Japan
TEL
03-3813-3111
Homepage URL
tomoyosi@juntendo.ac.jp
Sponsor or person
Institute
Department of Internal Medicine,Juntendo University
Institute
Department
Personal name
Funding Source
Organization
Department of Internal Medicine,Juntendo University
Organization
Division
Category of Funding Organization
Other
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Address
Tel
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2011 | Year | 10 | Month | 01 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Completed
Date of protocol fixation
| 2011 | Year | 09 | Month | 30 | Day |
Date of IRB
Anticipated trial start date
| 2011 | Year | 10 | Month | 01 | Day |
Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Management information
Registered date
| 2011 | Year | 10 | Month | 01 | Day |
Last modified on
| 2013 | Year | 10 | Month | 02 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000007497
